BOSTON - eTradeWire -- The Neuroendocrine Tumor Research Foundation (NETRF), the largest global funder of neuroendocrine cancer research, announces the start of their 2025 request for applications process. Scientists have until 5 p.m. EST on March 17, 2025, to submit their letter of intent.

NETRF offers four types of neuroendocrine cancer research awards (Accelerator, Investigator, Pilot, and Mentored Research Awards) with grants ranging from $90,000 to $800,000 over one to four years. They support scientists who conduct highly innovative research, whose work will help provide insight into the causes of neuroendocrine cancer and lead to improved treatments for patients.

"NETRF is the lifeline for dedicated scientists working tirelessly to unravel the complexities of this uncommon and challenging disease," said Elyse Gellerman, NETRF's chief executive officer. "NETRF is making the impossible, possible by accelerating leading-edge research in early detection and personalized treatments."

NETRF's grant process is rigorous and competitive. Requests for funding must be submitted for a specific research award. Applicants can submit their applications through ProposalCentral. (https://proposalcentral.com/default.asp) The timeline and process can be found on netrf.org/for-researchers/about/funding-for-researchers/apply-for-research-grants/.

More on eTradeWire News

• FreeTo.Chat - Silent Confessions, Expands U.S. Presence with Demand Growing for Secure, Non-AI, Adult Expression
• 17th Annual New Media Film Festival
• Phoenix Residents Can Enjoy Subtle Smile Transformations with Invisalign®
• Midwest Microbrew Features Duluth's Bent Paddle Brewing in Exclusive Interview
• HOBA Tech Reflects on 2025: Nine Years of Innovation and the Launch of HOBA Pro AI

NETRF recently announced its latest neuroendocrine cancer research grant recipients. The ten investigators receiving new awards are studying the most promising scientific approaches to understanding and treating neuroendocrine cancer. Funding for these ten grants totals $2 million, bringing NETRF's all-time investment in research to $39.8 million. Since its founding in 2005, NETRF has funded 156 research projects at 76 institutions in 17 countries worldwide.

"Our role of building and nurturing the neuroendocrine cancer research community is vital. NETRF is often the sole source of funding for early-career scientists with groundbreaking ideas," said Todd Gilman, president of NETRF's board of directors. "We're proud that the innovative researchers we've funded are making important discoveries that will have positive impacts on the patient community."

Click here (https://bit.ly/NETRFPressMaterials) for press release and images.

Sign up for newsletters (https://netrf.org/about-netrf/) to stay updated on the latest news in neuroendocrine cancer research and future symposia.

More on eTradeWire News

• Rich Florals Celebrates Grand Opening of Luxury Rose Studio in Woodbridge with Mayor McCormac
• Home Service Contractors Missing Out on Thousands of Monthly Searches, New Analysis Show
• Kindred Spirits: A Devotional for Those Loving Someone Through Addiction
• Tawanna Chamberlain Launches New Book, Outsized Ambition: The Blueprint for Going Beyond!
• Global Missions Chief, Anton Williams, Leads Grand Rapids MI Based Company to Updated MedTech

About NETRF

The mission of the Neuroendocrine Tumor Research Foundation (NETRF) is to fund research to discover cures and more effective treatments for neuroendocrine cancers. NETRF is the largest global funder of neuroendocrine cancer research and the preeminent resource for expert patient education and support.

NETRF is a 501(c)(3) organization. All contributions are tax-deductible to the extent allowed by law. Get Involved, Donate, Learn More: Visit www.NETRF.org for more.

Follow NETRF:

• Facebook: https://www.facebook.com/NETRF/
• X: https://x.com/CureNETs
• Instagram: https://www.instagram.com/netresearch/
• LinkedIn: https://www.linkedin.com/company/netrf/